

References

I-31

1. ACTEMRA® (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 04/2011. Revised 10/2013, 03/2017, 05/2017.
2. Burmester G, Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). *Ann Rheum Dis*. 2014;73(1):69–74.
3. Ringold S, Weiss P, Beukelman T. 2013 Update of the 2011 American College of Rheumatology Recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis & Rheumatism*. 2013;65(10):2499-2512.
4. Curtis J, Sarsour K, Napalkov P, et al. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. *Arthritis Research & Therapy*. 2015;17:319.
5. De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from a phase III trial. *Arthritis Rheumatology*. 2015;67(3):840-848.
6. Flipo R, Mailefert J, Chazerain P, et al. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: Results at 1 year of the ACT-SOLO study. *RMD Open*. 2017;3(1):e000340.
7. Yokota S, Itoh Y, Monio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: Results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. *Ann Rheum Dis*. 2016;75(9):1654–1660.
8. Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. *Arthritis Res Ther*. 2016;18: 272.
9. Singh J, Saag K, Bridges L, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
10. Czihal, M. Targeting Interleukin-6 in the treatment of giant cell arteritis: Hope or hype? *Vasa*. 2016;45(5):427.
11. Pascart T, Philippe P, Drumez E, et al. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. *International Journal of Rheumatic Diseases*. 2016;1093–1102.
12. MICROMEDEX®SOLUTIONS Compendia. 2017. Tocilizumab.
13. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Tocilizumab.
14. Roddy JVF, Haverkos BM, McBride A, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. *Leukemia & Lymphoma*. 2016;81-85.
15. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.

16. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016. Accessed September 29, 2017.
17. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).
18. MICROMEDEX®SOLUTIONS Compendia. 2017. Tocilizumab.
19. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Tocilizumab.